Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 3 · newest first

  1. New Insights into the Role of Clonotypic B Cells in Plasma-cell NeoplasiaBlood Cancer Discovery · 2026
  2. RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBlood Cancer Discovery · 2026
  3. Rewiring the Leukemic Genome: 3D Chromatin Architecture in B-cell Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2026
  4. Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid LeukemiaBlood Cancer Discovery · 2026
  5. Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell LymphomaBlood Cancer Discovery · 2026
  6. Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic ApproachesBlood Cancer Discovery · 2026
  7. Highlighted Research ArticlesBlood Cancer Discovery · 2026
  8. A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaBlood Cancer Discovery · 2026
  9. Outstanding Questions to Understand and Target Splicing Factor–Mutant Blood CancersBlood Cancer Discovery · 2026
  10. Improving Knowledge and Care of Patients with AML: The Need to Get Out of Our Comfort ZoneBlood Cancer Discovery · 2026
  11. MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemiaBlood Cancer Discovery · 2026
  12. CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular TherapyBlood Cancer Discovery · 2026
  13. 3D chromosome remodeling in B-cell development and acute lymphoblastic leukemiaBlood Cancer Discovery · 2026
  14. Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialBlood Cancer Discovery · 2026
  15. Genomic Insights into the Biology of T-lineage Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2026
  16. Models, Models, Everywhere: But Which One Should Guide Care?Blood Cancer Discovery · 2026
  17. Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALLBlood Cancer Discovery · 2026
  18. Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel TherapyBlood Cancer Discovery · 2026
  19. Two Costimulations Are Better Than One: Role of Endogenous CD28 in 4-1BB CAR T CellsBlood Cancer Discovery · 2026
  20. Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancersBlood Cancer Discovery · 2026
  21. Reading the “T” Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple MyelomaBlood Cancer Discovery · 2026
  22. Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple MyelomaBlood Cancer Discovery · 2026
  23. Highlighted Research ArticlesBlood Cancer Discovery · 2026
  24. The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic OpportunitiesBlood Cancer Discovery · 2026
  25. Multiplexed imaging reveals immune-metabolic niches in multiple myeloma linked to progression and bone diseaseBlood Cancer Discovery · 2026
  26. Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyBlood Cancer Discovery · 2026
  27. Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II studyBlood Cancer Discovery · 2026
  28. Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating AgentsBlood Cancer Discovery · 2026
  29. Remodeling of Mitochondrial Networks: Cellular Adaptation and Microenvironmental Reprogramming in Hematologic MalignanciesBlood Cancer Discovery · 2026
  30. First-line Therapy in Newly Diagnosed Multiple MyelomaBlood Cancer Discovery · 2026
  31. Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based CombinationsBlood Cancer Discovery · 2026
  32. A Triumvirate of Transformation: Oncogene, Ontogeny, and PlasticityBlood Cancer Discovery · 2026
  33. Seeing Is Believing: IEC-HS after CAR T CellsBlood Cancer Discovery · 2026
  34. Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsBlood Cancer Discovery · 2026
  35. Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic LeukemiaBlood Cancer Discovery · 2026
  36. Expectations and Limitations of Artificial Intelligence in Blood Cancer DiagnosisBlood Cancer Discovery · 2026
  37. No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk MyelomaBlood Cancer Discovery · 2025
  38. (Sub)Clonal Wars: IFN Interference Yields the Upper HandBlood Cancer Discovery · 2025
  39. Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβBlood Cancer Discovery · 2025
  40. Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myelomaBlood Cancer Discovery · 2025
  41. Human TET2-mutant clonal hematopoiesis expansion is driven by distinct inflammatory signaling responses in stem cells versus myeloid progeny.Blood Cancer Discovery · 2025
  42. Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic LeukemiaBlood Cancer Discovery · 2025
  43. Nuclear Export Gone Rogue: XPO1’s Chromatin Side Hustle Fuels LeukemiaBlood Cancer Discovery · 2025
  44. Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in LymphomaBlood Cancer Discovery · 2025
  45. Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in LymphomaBlood Cancer Discovery · 2025
  46. Nuclear Export Gone Rogue: XPO1’s Chromatin Side Hustle Fuels LeukemiaBlood Cancer Discovery · 2025
  47. Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentBlood Cancer Discovery · 2025
  48. Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor MicroenvironmentBlood Cancer Discovery · 2025
  49. The Global State of Blood Cancers: An Ongoing ChallengeBlood Cancer Discovery · 2025
  50. The Link between Modifiable Risk Factors and Myeloid Disorders—From Plate to PathogenesisBlood Cancer Discovery · 2025